Combined Patient, Physician Intervention Ups Function in OA

Share this content:
Combined Patient, Physician Intervention Ups Function in OA
Combined Patient, Physician Intervention Ups Function in OA

TUESDAY, Dec. 22, 2015 (HealthDay News) -- For patients with hip and knee osteoarthritis, a combined patient and provider intervention is associated with modest improvements in function, according to a study published online Dec. 22 in the Annals of Internal Medicine.

Kelli D. Allen, Ph.D., from the Durham VA Medical Center at Duke University in North Carolina, and colleagues examined the effectiveness of a combined patient and provider intervention for improving osteoarthritis outcomes in a cluster randomized trial. Participants included 30 providers and 300 outpatients with symptomatic hip or knee osteoarthritis. The patient intervention was telephone based and focused on weight management, physical activity, and cognitive behavioral pain management, while the provider intervention involved patient-specific osteoarthritis treatment recommendations delivered to primary care providers via the electronic medical record.

The researchers found that Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores were 4.1 points lower in the osteoarthritis intervention group at 12 months (P = 0.009). The intervention group also had WOMAC function subscale scores that were 3.3 points lower (P = 0.005). There was no significant between-group difference in WOMAC pain subscale scores (P = 0.126) or in physical performance and depressive symptoms. More patients in the osteoarthritis intervention group received provider referral for recommended osteoarthritis treatments, although the number actually receiving the treatments did not differ between the groups.

"The combined patient and provider intervention resulted in modest improvement in self-reported physical function in patients with hip and knee osteoarthritis," the authors write.

Several authors disclosed financial ties to the pharmaceutical and nutrition industries, as well as pharmacies.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths